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Cystatin C is an endogenous glomerular filtration marker
hence its serum level is affected by the glomerular filtration
rate (GFR). To study what other factors might affect it blood
level we performed a cross-sectional analysis of 3418 patients
which included a pooled dataset of clinical trial participants
and a clinical population with chronic kidney disease. The
serum cystatin C and creatinine levels were related to clinical
and biochemical parameters and errors-in-variables models
were used to account for errors in GFR measurements. The
GFR was measured as the urinary clearance of 125I-
iothalamate and 51Cr-EDTA. Cystatin C was determined at a
single laboratory while creatinine was standardized to
reference methods and these were 2.1þ /1.1 mg/dL and
1.8þ /0.8 mg/L, respectively. After adjustment for GFR,
cystatin C was 4.3% lower for every 20 years of age, 9.2%
lower for female gender but only 1.9% lower in blacks.
Diabetes was associated with 8.5% higher levels of cystatin C
and 3.9% lower levels of creatinine. Higher C-reactive protein
and white blood cell count and lower serum albumin were
associated with higher levels of cystatin C and lower levels of
creatinine. Adjustment for age, gender and race had a
greater effect on the association of factors with creatinine
than cystatin C. Hence, we found that cystatin C is affected by
factors other than GFR which should be considered when the
GFR is estimated using serum levels of cystatin C.
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Estimates of glomerular filtration rate (GFR) are essential to
the clinical assessment of kidney function and facilitate the
detection, evaluation, and management of chronic kidney
disease (CKD).1 GFR-estimating equations are based on
serum levels of endogenous filtration markers in combina-
tion with other variables; however, serum levels of these
markers are affected by factors other than GFR. GFR-
estimating equations based on serum creatinine, such as the
Modification of Diet in Renal Disease (MDRD) Study
equation, include the variables age, sex, and race as surrogates
for creatinine generation by muscle.2,3 However, these
variables do not account for variation in creatinine genera-
tion due to diet, physiological, or clinical conditions that
affect muscle mass. Consequently, GFR estimates based on
serum creatinine may be inaccurate in healthy people with a
high or low meat intake, building muscle, and in patients
with illnesses complicated by malnutrition, inflammation, or
deconditioning.
Cystatin C is an endogenous, 13 kDa protein filtered by
the glomeruli and reabsorbed and catabolized by epithelial
cells of the proximal tubule with only small amounts excreted
in the urine. Cystatin C is being considered as a potential
replacement for serum creatinine because it appears to be less
affected by muscle mass.4 However, recent reports have
shown substantial variability in the relationship between GFR
and cystatin C among populations, suggesting that there
may be differences in generation, tubular reabsorption, or
extra-renal elimination.5 Such differences would affect the
interpretation of GFR estimates based on cystatin C.
Using a large, pooled database from three research studies
and one clinical population, we have previously reported that
a GFR-estimating equation based on cystatin C was nearly as
accurate as estimates based on creatinine, thus providing an
alternative GFR estimate that is not linked to muscle mass. In
this study, we examine the association of factors other than
GFR to predict serum cystatin C and compare those
associations to prediction of creatinine. Because GFR is
measured with error, we used multivariable models that
adjust for measured GFR and also incorporated estimates of
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GFR measurement error. These results will better inform
us of the utility of cystatin C as an endogenous filtration
marker.
RESULTS
Table 1 summarizes the study characteristics and Table 2
details the clinical characteristics of participants in each study
and overall. Mean measured GFR (5th–95th percentile) was
48 (15–95) ml/min per 1.73 m2 (0.80 (0.25–1.58) ml/s per
1.73 m2). The mean standard deviation (s.d.) of serum
cystatin C and creatinine was 1.8 (0.8) mg/l (135 (60) nmol/l)
and 2.1 (1.1) mg/100 ml (186 (97) mmol/l), respectively. The
mean age was 52 years. All patients were considered to have
CKD.
In separate errors-in-variables models relating either log
cystatin C or log serum creatinine to log GFR after adjusting
for age, race, sex, and study, the coefficients for log GFR were
–67.0% (95% confidence intervals 66.3, 67.7) and
70.5% (69.8, 71.2), respectively. A coefficient of less
than 100% signifies that a percent change in GFR is
associated with smaller percent change in the serum levels
of cystatin C and creatinine, indicating an association of the
serum levels with factors other than GFR. A lower absolute
level for the association with GFR of cystatin C than
creatinine suggests factors other than GFR are more strongly
associated with cystatin C than with creatinine.
Tables 3 and 4 show the regression coefficients and 95%
confidence intervals relating serum cystatin C and creatinine
to potential predictor variables, after controlling for GFR and
study in models that adjust for measurement error in GFR
and after adjustment for age, sex, and race. The coefficient
represents the average percent difference in cystatin C or
creatinine level for a difference between the 75th and 25th
percentiles (the interquartile range, IQR) in the continuous
variables (age, body mass index, and blood and urine levels)
and for a difference between categories for dichotomous
predictor variables (sex, race, and diabetes). The smaller the
IQR, the larger the effect of a small change in the variable on
serum levels of the markers. Within each column, the
coefficients show the relative strength of association among
variables.
Figure 1 compares the regression coefficients for cystatin C
and creatinine that are displayed in Tables 3 and 4. Each plot
character represents a predictor variable. Distance of the plot
character from the zero on the horizontal and vertical axes
indicates the strength of association of the predictor variable
with level of cystatin C and creatinine, respectively. Panel A
shows that after adjustment for GFR and GFR measurement
error (but not age, race, and sex), older age and female sex
were associated with lower cystatin C (by 4.3 and 9.2%,
respectively) and lower creatinine (by 9.2 and 31.7%,
respectively). Black race was not significantly associated with
cystatin C (1.9%) but was associated with higher creatinine
levels (13.6%). Higher levels of height (4.8 and 21.8), weight
(6.0 and 12.9), body mass index (4.2 and 3.5), and urine
creatinine (4.1 and 19.2) were associated with higher levels of
cystatin C and creatinine, respectively, and, except for body
mass index, the magnitude of association was greater with
creatinine than with cystatin C. A higher level of urine
protein (on the log scale) was associated with a higher level of
cystatin C (12.1%) and creatinine (10.0%). Diabetes was
associated with higher levels of cystatin C (8.5%) and lower
levels of creatinine (3.0%). Similarly, higher C-reactive
protein and white blood cell count and lower serum albumin
were associated with higher levels of cystatin C (2.3, 3.1, and
1.9%, respectively) and lower levels of creatinine (3.3,
3.2, and 5.9%, respectively). Higher urine urea nitrogen
and urine phosphorus were associated with higher cystatin C
(5.3 and 7.7%, respectively) and creatinine (10.1 and 12.6%,
respectively).
Panel B of Figure 1 shows the same associations after
adjustment for age, sex, and race. Adjustment for age, sex,
and race markedly decreased the association of factors with
serum creatinine. In contrast, this adjustment had little effect
on the associations with serum cystatin C. After adjustment
for age, sex, and race, the strongest associations with cystatin
C were for proteinuria (10.8% on the log scale) and diabetes
(8.0%). Stronger associations were seen for cystatin C than
for serum creatinine for many variables (diabetes (8.0 vs
2.0%), systolic blood pressure (2.6 vs 0.8%), weight (5.2 vs
2.7%), body mass index (5.2 vs 2.5%), white blood cell count
(3.0 vs 1.8%), hemoglobin (3.2 vs 0.6%), C-reactive protein
(3.4 vs 0.9%), and urine protein (10.8 vs 5.1%)).
After accounting for GFR, its measurement error, as well
as age, sex, and race, the percent change for log creatinine in
predicting log cystatin C was 15.9% and the percent change
for log cystatin C in predicting log creatinine was 16.1%.
Serum urea nitrogen was also significantly associated with
both creatinine and cystatin C after adjustment for the same
factors.
DISCUSSION
Cystatin has been proposed as an alternative filtration marker
to serum creatinine, and it clearly has promise to be so. The
main findings of this study are that many factors other than
Table 1 | Study characteristics
Name MDRD Study AASK CSG NephroTesta
Type RCT RCT RCT CP
Location USA USA USA France
Center MC MC MC MC
N 1085 1205 266 438
Dates 1989–1992 1995–1998 1987–1992 2000–2004
Clearance method Urinary Urinary Urinary Urinary
Filtration marker Iothalamate Iothalamate Iothalamate EDTA
AASK, African American Study of Kidney Diseases and Hypertension; CP, clinical
population; CSG, Collaborative Study Group: Captopril in Diabetic Nephropathy
Study; EDTA, ethylenediaminetetraacetic acid. MC, multicenter; MDRD Study,
Modification of Diet in Renal Disease Study; RCT, randomized clinical trial.
aThe NephroTest initiative is a prospective hospital-based ongoing cohort that
began in 2000, enrolling patients with all diagnoses of CKD stage 2–5 referred for
extensive work-up by two nephrology departments. Data included in this study
were collected between 2000 and 2004. These data are part of the data set
presented in Froissart et al.26.
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GFR are associated with serum cystatin C, including key
variables such as diabetes, measures of body size, and
inflammation. These associations would lead to systematic
bias of GFR estimates based on cystatin C in selected
populations or clinical conditions as well as imprecision of
GFR estimates in all populations. Clinicians can use these
findings to aid in interpretation of serum levels and GFR
estimates based on cystatin C.
Physiological processes other than glomerular filtration,
such as tubular reabsorption or secretion, generation, and
extra-renal elimination can affect the serum levels of
endogenous filtration markers. Urinary excretion of the
marker facilitates study of these processes. For example, the
effect of medications on tubular secretion of creatinine was
verified by comparing creatinine clearance to GFR measured
using exogenous markers, and the relationship of muscle
mass and diet to creatinine generation was established from
studies of urinary excretion of creatinine. In addition, in
clinical practice, clinicians can measure urinary creatinine
excretion to assist in interpretation of unexpected values for
GFR estimates based on creatinine. In contrast, the absence of
urinary excretion of cystatin C makes it difficult to measure
these physiological processes and to interpret GFR estimates
from cystatin C in clinical practice. Instead, understanding of
the determinants of cystatin C other than GFR in humans
relies on epidemiological associations. Our study provides
the first comprehensive investigation of associations with
cystatin C to factors other than GFR.
We found a stronger association of serum creatinine than
cystatin C with surrogates of muscle mass, including age, sex,
race, and urine creatinine. This likely reflects smaller
contribution of muscle to generation of cystatin C mass
than creatinine. It is possible that GFR estimates based on
cystatin C may be more accurate than estimates based on
creatinine in patients with variation in creatinine generation
due to diet or clinical conditions that affect muscle mass.
This hypothesis has not been explicitly tested as such patients
have not been systematically included in research studies.
The relationship of race with cystatin C levels, indepen-
dent of GFR (to the best of our knowledge) has not been
previously noted by others. Similar to the findings here, when
we included age, sex, and race as coefficients in an equation
to estimate GFR from serum cystatin C, the coefficients for
these factors were significant but substantially smaller than in
Table 2 | Patient characteristics: overall and by study
Overall MDRD AASK CSG NephroTesta
Variable N Mean/% IQR N Mean/% s.d. N Mean/% s.d. N Mean/% s.d. N Mean/% s.d.
Age (years) 3418 53.2 19 1047 52 13 1647 54 10 287 34 8 438 59 15
Female 3418 32. 1047 39.1 1647 35.9 287 46.9 438 28.8
Black 3418 53.5 1047 9.7 1647 100 287 7.7 438 8.5
Diabetes 3418 13.9 1047 5.7 1647 0 287 100 438 21.9
Hypertension 3417 66.7 1047 34.9 1646 99.7 287 34.6 438 40.0
Systolic blood pressure (mm Hg) 3404 139 28 1047 132 18 1647 150 23 287 135.6 17.2 424 138.3 20.0
Diastolic blood pressure (mm Hg) 3239 88 19 1047 81 10 1647 96 14 287 82.9 10.2 259 78.0 11.1
BMI (kg/m2) 3416 27.7 7 1046 27 4 1647 31 7 286 25.5 4.9 438 26.0 4.6
GFR (ml/min per 1.73 m2) 3418 44.4 34 1047 33 14 1647 57 23 287 74.8 32.5 438 33.6 16.8
Serum creatinine (mg/100 ml) 3418 1.8 1 1047 2.34 1.09 1647 1.71 0.82 286 1.33 0.56 438 2.54 1.22
Blood urea nitrogen (mg/100 ml) 3224 25.0 18 1047 36.3 14.5 1647 22.6 11.4 287 25.6 15.7 244 43.6 20.4
Cystatin C (mg/l) 3418 1.6 1 1047 2.3 0.8 1647 1.5 0.7 287 1.4 0.7 438 2.2 0.8
Hemoglobin (g/100 ml) 2856 13.3 2 1014 13.0 1.9 1557 13.3 1.7 286 13.2 2.0 0 . .
Potassium (mEq/l) 2968 4.2 1 1035 4.3 0.6 1647 4.2 0.6 287 4.3 0.5 0 . .
Bicarbonate (mEq/l) 3335 25.0 4 1036 23 4 1647 25 3 285 26.1 3.3 368 25.5 3.2
Glucose (mg/100 ml) 2969 92.0 21 1036 93 26 1647 95 18 287 234 125 0 . .
Calcium (mg/100 ml) 2962 9.1 1 1029 9.1 0.5 1647 9.2 0.5 287 9.0 0.6 0 . .
Phosphate (mg/100 ml) 2974 3.6 1 1042 3.9 0.8 1647 3.5 0.7 286 3.7 0.7 0
Albumin (g/100 ml) 3381 4.2 1 1047 4.0 0.4 1647 4.3 0.4 285 3.7 0.5 403 4.1 0.5
Total protein (g/100 ml) 2980 7.0 5 1047 2.1 0.8 1647 7.6 0.6 287 6.6 0.7 0 . .
Total cholesterol (mg/100 ml) 2683 209.0 60 1041 216 46 1642 211 46 0 . . 0 . .
C-reactive protein (g/100 ml) 2997 0.4 1 1026 0.3 0.5 1643 0.4 0.6 0 . . 328 2.3 5
Hemoglobin A1c (g/100 ml) 1032 5.6 0.9 1032 5.6 0.9 0 . . 0 . . 0 . .
Urine creatinine (mg/day) 3008 1458 772 943 1406 420 1556 1679 659 247 1432 1262 262 1294 418
Urine urea nitrogen (g/day) 2896 8.7 5 943 9.4 2.9 1565 8.7 3.9 154 11.0 4.3 234 9.6 3.2
Urine protein (mg/day) 2755 165 986 943 330 1450 1565 71 353 247 1677.0 3133 0 . .
AASK, African American Study of Kidney Diseases and Hypertension; BMI, body mass index; CSG, Collaborative Study Group: Captopril in Diabetic Nephropathy Study; GFR,
glomerular filtration rate; IQR, interquartile range; MDRD Study, Modification of Diet in Renal Disease Study; s.d., standard deviation.
aThe NephroTest initiative is a prospective hospital-based ongoing cohort that began in 2000, enrolling patients with all diagnoses of CKD stage 2 to 5 referred for extensive
work-up by two nephrology departments. Data included in this study were collected between 2000 and 2004. These data are part of the dataset presented in Froissart et al.26
To convert GFR from ml/min per 1.73 m2 to ml/s per 1.73 m2, multiply by 0.01667; to convert serum creatinine from mg/100 ml to mmol/l, multiply by 88.4; to convert blood
urea nitrogen from mg/100 ml to mmol/l, multiply by 0.357; to convert cystatin C from mg/l to nmol/l, multiply by 74.9; to convert hemoglobin from g/100 ml to g/l, multiply
by 10; to convert potassium from mEq/l to mmol/l, multiply by 1; to convert bicarbonate from mEq/l to mmol/l, multiply by 1; to convert glucose from mg/100 ml to mmol/l,
multiply by 0.05551; to convert calcium from mg/100 ml to mmol/l, multiply by 0.2495; to convert phosphate from mg/100 ml to mmol/l, multiply by 0.3229; to convert
albumin from g/100 ml to g/l, multiply by 10; to convert total protein from g/100 ml to g/l, multiply by 10; to convert total cholesterol from mg/100 ml to mmol/l, multiply by
0.02586; to convert C-reactive protein from g/100 ml to nmol/l, multiply by 95,240; to convert hemoglobin A1C from g/100 ml to g/l, multiply by 10; to convert urine
creatinine from mg/day to g/day, divide by 1000; to convert urine protein from mg/day to g/day, divide by 1000.
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equations to estimate GFR from serum creatinine.4 The
association with race varies by modeling strategy and
weakened by adjustment for measurement error in GFR in
this paper compared to the GFR-estimating equation. In
contrast, in analyses from the National Health and Nutrition
Examination Survey, we previously reported differences in
serum levels of cystatin C among races, even among young
healthy individuals in whom GFR is presumably normal.6
Possibly, this could not only reflect true differences in GFR
among race groups, such as hyperfiltration among African
Americans compared to whites, but also reflect variation in
other characteristics among the race groups in the National
Health and Nutrition Examination Survey. GFR measure-
ments in a representative multiethnic population will be
necessary to determine whether the cause of variation in
cystatin C levels reflects variation in measured GFR or in
factors affecting cystatin C other than GFR.
We also observed stronger magnitude of associations of
body mass index and weight with cystatin C than with
creatinine, which may indicate an association of cystatin C
with fat mass. In this context, the association of higher
cystatin C with diabetes may, in part, also reflect the
association with fat mass. These are important
considerations for use of cystatin C in clinical practice, given
the high and increasing prevalence of obesity and diabetes.7
The association of proteinuria with higher cystatin C may
reflect the association of diabetes with proteinuria in our
data set but could also reflect tubular damage. The
association of higher urine urea nitrogen and urine
phosphate with higher serum levels of both markers after
Table 3 | Percent change in level of cystatin C
Not adjusted Adjusted for GFR
Adjusted for GFR
measurement error (0.015)
Adjusted for GFR measurement
error (0.015), age, sex, and race
Variable IQR Coeff L H Coeff L H Coeff L H Coeff L H
Age* (years) 19.38 5.5 2.0 9.2 3.8 5.2 2.5 4.3 5.7 2.9
Female* 1 0.7 5.2 3.9 8.8 10.6 7.0 9.2 11.0 7.4
Black 1 36.1 38.7 33.4 4.1 6.1 2.0 1.9 4.0 0.3
Diabetes 1 14.5 20.3 8.2 7.3 3.9 10.9 8.5 5.0 12.2 8.0 4.2 12.1
Hypertension 1 23.8 27.2 20.3 1.2 3.2 0.8 0.1 2.0 2.2 2.6 0.2 5.5
Height* (cm) 14.4 2.1 5.3 1.2 4.5 3.0 6.0 4.8 3.3 6.3 0.5 2.4 1.4
Weight* (kg) 25.2 7.6 10.2 5.0 5.4 4.0 6.7 6.0 4.7 7.4 5.2 3.7 6.6
BMI* (kg/m2) 7.29 7.0 9.3 4.5 3.6 2.4 4.9 4.2 2.9 5.5 5.2 3.9 6.6
Systolic blood pressure*
(mm Hg)
28 2.5 5.1 0.2 1.3 0.0 2.6 1.5 0.2 2.8 2.6 1.2 4.0
Diastolic blood pressure
(mm Hg)
19 15.4 17.9 12.8 0.0 1.3 1.5 0.9 0.5 2.3 0.4 1.2 1.9
Log serum creatinine*
(mg/100 ml)
0.65 123.5 120.2 126.8 35.0 31.0 39.1 20.4 15.8 25.2 15.9 14.2 17.6
Log SUN* (mg/100 ml) 0.69 95.3 91.0 99.7 14.8 12.0 17.5 7.7 4.9 10.5 6.5 0.1 13.5
Hemoglobin* (g/100 ml) 2.4 22.3 24.7 19.9 3.1 1.6 4.7 4.9 3.3 6.6 3.2 0.5 5.9
Log WBC* (cells/ml) 0.4 8.0 4.5 11.5 3.3 1.7 5.0 3.1 1.5 4.8 3.0 1.4 4.5
Sodium (mEq/l) 4 1.1 3.6 1.4 0.4 0.6 1.5 0.5 0.5 1.6 0.8 0.8 2.4
Potassium (mEq/l) 0.7 17.1 13.0 21.3 1.3 0.1 2.8 0.5 0.9 2.0 0.0 1.1 1.0
Bicarbonate (mEq/l) 4 26.4 28.0 24.7 2.8 4.0 1.5 1.2 2.5 0.2 0.9 2.2 0.5
Log glucose (mg/100 ml) 0.22 7.0 8.4 5.7 0.9 0.1 1.7 1.4 0.6 2.2 1.1 0.3 1.9
Albumin* (g/100 ml) 0.5 13.3 15.6 10.9 2.5 3.7 1.3 1.9 3.1 0.7 2.2 3.5 0.9
Calcium (mg/100 ml) 0.6 9.9 12.5 7.2 0.1 1.0 1.3 0.7 0.5 1.9 1.2 0.0 2.4
Phosphate (mg/100 ml) 0.8 32.9 27.9 38.1 1.6 0.3 2.9 0.1 1.4 1.3 0.1 1.4 1.3
Total cholesterol (mg/100 ml) 60 0.3 3.5 2.9 1.5 2.9 0.1 1.6 2.9 0.2 0.4 1.7 1.0
Log CRP* (g/100 ml) 1.75 10.1 7.0 13.3 2.6 1.3 4.0 2.3 0.9 3.7 3.4 1.9 4.9
Urine creatinine* (mg/day) 0.77 13.8 18.5 8.9 3.1 1.6 4.6 4.1 2.4 5.8 1.7 0.4 3.0
Urine phosphate* (mg/day) 0.38 14.6 18.4 10.7 6.4 4.1 8.7 7.7 5.4 10.1 5.8 3.4 8.3
Urine urea nitrogen* (g/day) 4.69 11.6 14.2 9.0 4.4 2.9 5.8 5.3 3.9 6.8 4.0 2.5 5.5
Log urine protein* (mg/day) 3.15 63.1 57.0 69.5 14.5 12.1 17.0 12.1 9.7 14.6 10.8 8.3 13.4
BMI, body mass index; Coeff, coefficient; CRP, C-reactive protein; GFR, glomerular filtration rate; H, higher confidence limit; IQR, interquartile range; L, lower confidence limit;
WBC, white blood cell.
Each row shows different models based on the variable. Continuous variables are expressed as interquartile range, which is the difference between the 25th and 75th
percentiles. The model in column 1 includes the variable adjusted for study. Column 2 includes the model adjusted for variable, study terms, GFR, and the interaction of GFR
and study. Column 3 includes the model adjusted for variable, study terms, GFR, GFR measurement error, and the interaction of GFR and study. Column 4 includes the model
adjusted for variable, study terms, GFR, GFR measurement error, the interaction of GFR and study, age, sex, and race. The coefficient is expressed as 100 (ecoeff1), which can
be interpreted as a geometric mean percent change in the filtration marker for a change of two quartiles in the variable.
*P-valueo0.0001 for the interaction of study variable in a model that includes variable, study terms, GFR, GFR measurement error, age, sex, and race, and interaction of
study by GFR and by variable.
To convert serum creatinine from mg/100 ml to mmol/l, multiply by 88.4; to convert SUN mg/100 ml to mmol/l, multiply by 0.357; to convert hemoglobin from g/100 ml to g/l,
multiply by 10; to convert WBC from 103/ml to 109/l, multiply by 1; to convert sodium from mEq/l to mmol/l, multiply by 1; to convert potassium from mEq/l to mmol/l,
multiply by 1; to convert bicarbonate from mEq/l to mmol/l, multiply by 1; to convert glucose from mg/100 ml to mmol/l, multiply by 0.05551; to convert albumin from
g/100 ml to g/l, multiply by 10; to convert calcium from mg/100 ml to mmol/l, multiply by 0.2495; to convert phosphate from mg/100 ml to mmol/l, multiply by 0.3229; to
convert total cholesterol from mg/100 ml to mmol/l, multiply by 0.02586l; to convert C-reactive protein from g/100 ml to g/l, multiply by 10; to convert urine creatinine from
mg/day to g/day, divide by 1000; to convert urine phosphate from mg/day to g/day, divide by 1000; to convert urine protein from mg/day to g/day, divide by 1000.
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adjustment for GFR suggests that diet may also be a
determinant of cystatin C.
Our findings of associations of cystatin C with body mass
index, as well as inflammation, and proteinuria are consistent
with previous reports.8–13 Recent studies have shown that in
studies of preadipocyte cell cultures, there is increased
cystatin C production during preadipocyte differentiation.14
As obesity is now recognized as an inflammatory state, the
findings of both inflammation and obesity are informative.
Other studies have also shown the association of cystatin C
with thyroid hormone levels.15 We were not able to verify
these data as thyroid hormone levels were not measured in
the current studies.
Many studies have shown stronger association of serum
cystatin C with mortality and cardiovascular disease than
serum creatinine, particularly in studies of older adults and
we have previously demonstrated higher levels of cystatin C
in older adults in the National Health and Nutrition
Examination Survey.6,16–19 In part, these findings may reflect
greater accuracy of cystatin C than creatinine as a filtration
marker in this population. Another possible explanation, as is
suggested by this study, is differential effects of factors other
than GFR on levels of serum cystatin C and creatinine that
are more prevalent in older adults.20 In this study, diabetes,
higher C-reactive protein, higher white blood cell count, and
lower serum albumin (all risk factors for mortality) were
associated with a higher serum cystatin C and lower serum
creatinine. The opposite direction of the relationships of
these factors to the filtration markers would confound the
comparison of the filtration markers in their prediction of
risk. These studies adjusted for many of the factors that we
identified, and therefore the findings in these studies may
Table 4 | Percent change in serum creatinine
Not adjusted Adjusted for GFR
Adjusted for GFR
measurement error (0.015)
Adjusted for GFR measurement
error (0.015), age, sex, and race
Variable (unit) IQR Coeff L H Coeff L H Coeff L H Coeff L H
Age* (years) 19.38 0.5 3.2 4.3 9.0 10.3 7.2 9.2 10.7 7.7
Female* 1 25 28.6 21.2 31.6 32.8 29.9 31.7 33.1 30.2
Black 1 28.3 31.5 24.8 12.5 8.1 13.8 13.6 10.7 16.7
Diabetes 1 24.7 30.0 18.9 4.4 8.3 1.6 3.9 7.3 0.4 2.0 2.0 6.2
Hypertension 1 18.7 22.7 14.5 7.3 3.8 9.2 7.9 5.2 10.7 0.4 2.3 3.1
Height* (cm) 14.4 13.4 9.5 17.4 21.6 19.4 23.4 21.8 19.8 23.8 0.5 1.5 2.5
Weight* (kg) 25.2 2.3 5.1 0.6 12.6 10.4 13.8 12.9 11.1 14.6 2.7 1.3 4.2
BMI* (kg/m2) 7.29 7.8 10.3 5.2 3.3 1.4 4.5 3.5 2.0 5.1 2.5 1.2 3.9
Systolic blood pressure*
(mm Hg)
28 3.2 6.0 0.4 0.8 0.9 2.3 0.9 0.7 2.5 0.8 2.1 0.6
Diastolic blood pressure
(mm Hg)
19 10.7 13.5 7.8 6.9 4.5 8.1 7.2 5.4 9.1 1.1 2.7 0.6
Log serum cystatin C(mg/l) 0.65 151.3 146.2 156.5 45.9 51.0 66.3 36.2 27.7 45.1 16.1 8.7 24.1
Log SUN* (mg/100 ml) 0.69 104.1 99.1 109.3 18.6 19.4 26.5 15.7 12.1 19.3 16.1 12.8 19.4
Hemoglobin* (g/100 ml) 2.4 20.3 22.9 17.5 7.9 4.9 8.6 8.6 6.7 10.6 0.6 1.1 2.3
Log WBC* (cells/ml) 0.4 1.4 1.9 4.8 3.1 4.7 1.2 3.2 5.0 1.4 1.8 3.3 0.2
Sodium (mg/100 ml) 4 0.8 2.0 3.6 2.4 1.1 3.6 2.5 1.2 3.7 0.7 0.4 1.8
Potassium (mEq/l) 0.7 19.4 14.9 24.0 2.8 1.4 5.1 2.5 0.7 4.3 0.9 0.5 2.3
Bicarbonate (mEq/l) 4 26.7 28.6 24.8 1.6 4.2 1.0 0.9 2.6 0.8 0.7 2.1 0.8
Log glucose (mg/100 ml) 0.22 8.7 10.0 7.4 0.7 1.7 0.2 0.5 1.3 0.3 0.2 0.6 1.1
Albumin* (g/100 ml) 0.5 6.9 9.5 4.2 5.6 3.8 6.7 5.9 4.4 7.4 2.3 1.0 3.6
Calcium (mg/100 ml) 0.6 11.9 14.6 9.0 1.7 3.5 0.5 1.5 3.0 0.0 0.2 1.4 1.1
Phosphate (mg/100 ml) 0.8 35 30.1 40.0 2.2 1.6 4.9 1.5 0.2 3.3 3.2 1.9 4.7
Total cholesterol (mg/100 ml) 60 3.4 6.7 0.1 4.5 6.2 2.8 4.6 6.3 2.8 0.4 1.0 1.8
Log CRP* (g/100 ml) 1.75 4.3 1.2 7.6 3.1 4.4 1.4 3.3 4.8 1.7 0.4 0.9 1.8
Urine creatinine* (mg/day) 0.77 2.7 5.1 0.3 18.7 11.1 25.3 19.2 11.8 27.1 7.8 4.4 11.3
Urine phosphate* (mg/day) 0.38 14.3 18.6 9.8 11.9 8.0 13.9 12.6 9.5 15.7 5.9 3.1 8.7
Urine urea nitrogen* (g/day) 4.69 8.1 10.8 5.2 9.7 7.4 10.9 10.1 8.4 11.9 6.1 4.5 7.7
Log urine protein* (mg/day) 3.15 61.0 54.4 67.9 10.9 9.6 15.2 10.0 7.2 12.8 5.1 2.7 7.5
BMI, body mass index; Coeff, coefficient; CRP, C-reactive protein; GFR, glomerular filtration rate; H, higher confidence limit; IQR, interquartile range; L, lower confidence limit;
WBC, white blood cell.
Each row shows different models based on the variable. Continuous variables are expressed as interquartile range, which is the difference between the 25th and 75th
percentiles. The model in column 1 includes the variable adjusted for study. Column 2 includes the model adjusted for variable, study terms, GFR, and the interaction of GFR
and study. Column 3 includes the model adjusted for variable, study terms, GFR, GFR measurement error, and the interaction of GFR and study. Column 4 includes the model
adjusted for variable, study terms, GFR, GFR measurement error, the interaction of GFR and study, age, sex, and race. The coefficient is expressed as 100 (ecoeff1), which can
be interpreted as a geometric mean percent change in the filtration marker for a change of two quartiles in the variable.
*P-value o 0.0001 for the interaction of study variable in a model that includes variable, study terms, GFR, GFR measurement error, age, sex, and race, and interaction of
study by GFR and by variable.
To convert serum creatinine from mg/100 ml to mmol/l, multiply by 88.4; to convert SUN mg/100 ml to mmol/l, multiply by 0.357; to convert hemoglobin from g/100 ml to g/l,
multiply by 10; to convert WBC from 103/ml to 109/l, multiply by 1; to convert sodium from mEq/l to mmol/l, multiply by 1; to convert potassium from mEq/l to mmol/l,
multiply by 1; to convert bicarbonate from mEq/l to mmol/l, multiply by 1; to convert glucose from mg/100 ml to mmol/l, multiply by 0.05551; to convert albumin from
g/100 ml to g/l, multiply by 10; to convert calcium from mg/100 ml to mmol/l, multiply by 0.2495; to convert phosphate from mg/100 ml to mmol/l, multiply by 0.3229; to
convert total cholesterol from mg/100 ml to mmol/l, multiply by 0.02586; to convert C-reactive protein from g/100 ml to g/l, multiply by 10; to convert urine creatinine from
mg/day to g/day, divide by 1000; to convert urine phosphate from mg/day to g/day, divide by 1000; to convert urine protein from mg/day to g/day, divide by 1000.
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reflect residual confounding due to errors in measurements
of these factors or confounding by other unmeasured and
unknown factors.
The associations of cystatin C with non-GFR determinants
that we report in this study, although are significant, are
relatively small. The observed effect sizes reflect the average
levels within the current study population and are likely to be
larger in individual patients or in populations with selected
clinical conditions, such as the obese, the chronically ill, or those
with high levels of inflammation. Larger-than-average effects of
non-GFR determinants could lead to important errors in GFR
estimation from serum cystatin C in individual patients and
systematic bias in selected populations. Rule et al.21 showed that
bias of cystatin C-based estimating equation differed among
patients with native kidney disease, kidney transplant recipients,
and potential kidney donors, consistent with systematic
differences in non-GFR determinants of cystatin C among
these populations. Similarly, variation in non-GFR determinants
would explain the observed imprecision of cystatin C-based
estimating equations even in relatively homogenous populations
with known CKD.4
Clinicians can use knowledge of non-GFR determinants of
cystatin C to assist in interpretation of serum levels and GFR
estimates based on cystatin C. This is analogous to the
interpretation of GFR estimates based on knowledge of non-
GFR determinants of serum creatinine. For example, because
the relationship between serum creatinine and muscle mass is
understood, an attentive clinician can interpret the level of
the serum creatinine or the estimated GFR differently in a
patient with vs without muscle wasting, even though there is
no term for muscle wasting in the GFR-estimating equation.
As such, our data suggest that the value of a cystatin C level
should be interpreted with knowledge of several factors, such
as obesity, inflammation, and diabetes.
Strengths of the study include the large study population
composed of 3418 patients with CKD in three research studies
and one clinical population, measurement of cystatin C in a
single laboratory, calibration of the creatinine assays in each
study to standardized values, careful measurement of GFR using
urinary clearances of exogenous filtration markers, use of
analytical techniques that incorporated measurement error in
GFR, and the large number of potential predictors available.
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Figure 1 | Comparison of coefficients of variables predicting log cystatin and log creatinine. Solid diagonal line is the line of identity.
For continuous predictor variables the coefficients are expressed as the percent differences in cystatin or creatinine associated with a
difference of one interquartile range in the predictor variable (i.e., a change from the 25th to 75th percentile) after adjusting for GFR in
models that incorporate measurement error in the GFR assay. For dichotomous predictor variables the coefficients indicate the percent
differences in cystatin or creatinine associated with the presence vs the absence of the factor. Variables that fall along the line of identity
have a similar relationship to serum creatinine and cystatin C. Points away from the line of identity represent variables with a different
magnitude of association with cystatin C and creatinine. Variables near the origin have a weak relationship with the filtration marker. The
plot character colors indicate significance of the relationships between the predictor variable to cystatin C, creatinine, neither or both. Gray
dots indicate variables that were not significantly associated with either cystatin C or creatinine. For all variables, the coefficients for cystatin
C and creatinine were significantly different from one other (Po0.001). HTN, hypertension; BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; WBC, white blood cell count; Na, sodium; K, potassium; Pi,
phosphate; Ca, calcium; HCO3, bicarbonate; TC, total cholesterol; alb, albumin; gluc, glucose; UUN, urine urea nitrogen; UCR, urine
creatinine; UPI, urine phosphate; UPR, urine protein. (a) After adjustment for GFR and GFR measurement error. Variables that were not
significantly associated with either variable (indicated by gray dots) include serum bicarbonate, total calcium, and phosphate. Sex is
indicated on the margins of the figure as a downward arrow, as the coefficients are bigger than the scale. (b) After adjustment for GFR and
GFR measurement error, age, sex, and race. Variables that were not significantly associated with either cystatin C or creatinine (indicated by
gray dots) include hypertension, height, diastolic blood pressure, sodium, bicarbonate, total calcium, and total cholesterol.
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There are also several limitations. First, we have shown results
of associations of single variables, adjusted only for GFR, age, sex,
and race, rather than a full multivariable adjustment. Second,
incomplete adjustment for measurement error and biological
variation in GFR may lead to residual confounding between
variables associated with GFR and cystatin C, which could
explain the association of serum cystatin C and creatinine with
each other and with serum urea nitrogen even after adjustment
for GFR. We estimated the level of measurement error in only
two of the studies: MDRD Study and the African American Study
of Kidney Disease and Hypertension (AASK). Possibly, the
measurement error may be different in the other two studies
included in the pooled database. Third, the study population was
restricted to patients with native kidney disease and without
serious comorbid conditions that would exclude them from
participating in clinical trials. Fourth, study participants were
likely selected in part on the basis of previous creatinine values,
which can lead to a bias in the estimated regression coefficients
for creatinine and cystatin, as cystatin C remained associated with
creatinine after controlling for GFR. Nevertheless, all studies were
of CKD populations and previous studies have suggested that for
creatinine-based estimating equations differences among sub-
groups based on demographic characteristics are minimal for
populations with native kidney disease.1,22 Finally, the data are
pooled from multiple studies and there is variation among
studies in some of the observed relationships. This variation may
be due to population differences or differences in how the
covariates were ascertained or measured.
In summary, although cystatin has promise as an
alternative filtration marker to creatinine, like creatinine,
cystatin C is affected by factors other than GFR that must be
considered in interpretation of its serum level in clinical
practice. The best GFR estimate may be the combination or
sequential use of both filtration markers, with the expectation
that the use of both markers minimizes the impact of
physiological processes other than GFR that affect each
marker. Further research is required to better understand the
non-GFR determinants of cystatin C across a broader range
of populations and to define the use of both creatinine and
cystatin C in GFR estimation.
MATERIALS AND METHODS
Sources of data
Chronic Kidney Disease Epidemiology Collaboration is a research
group formed to develop and validate improved estimating
equations for GFR by pooling data from research studies and
clinical populations (hereafter referred to as ‘studies’).4 The current
analysis is based on a pooled data set of individual patient data from
four studies where frozen samples were available for assay of cystatin
C: MDRD Study, AASK, Collaborative Study Group (CSG)
Study,2,3,5,23–25 and the NephroTest cohort, a clinical population in
Paris, France26 (Table 1). Data from the baseline examination for
these studies were used.
Measurements
GFR was measured as four period urinary clearances of
125I-iothalamate in the MDRD Study, AASK and CSG, and as five
period urinary clearances of 51Cr-EDTA in NephroTest and is
reported adjusted for body surface area (Table 1). Comparisons of
125I-iothalamate and 51Cr-EDTA clearances to urinary clearance of
inulin, the reference standard for GFR measurements, demonstrated
high correlation.26–28 Samples were assayed for cystatin C with a
particle-enhanced immunonephelometric assay (N Latex Cystatin C,
Dade Behring, IL, USA) in samples stored at 80 1C. The inter- and
intraassay coefficients of variation for cystatin C were 3.2–4.4 and
2.0–3.0%, respectively. Stability in serum stored at 80 1C has been
demonstrated.29 Serum creatinine assays were calibrated to stan-
dardized serum creatinine values at the Cleveland Clinic Research
Laboratory.1,22 The results of the calibration procedures have been
previously described.4,30
Variables
A potential list of variables that are hypothesized to affect serum
cystatin C or creatinine by mechanisms other than GFR (non-GFR
determinants) was developed from review of the literature and from
physiological and clinical considerations. Variables in the analysis
included measures of muscle mass and body size (age, sex, race,
height, weight, body mass index, urine creatinine), cardiovascular
disease risk factors (hypertension, diabetes, systolic blood pressure,
diastolic blood pressure, glucose, total cholesterol), measures related
to severity of kidney disease (hemoglobin, serum levels of sodium,
potassium, bicarbonate, calcium, phosphate, and urine protein),
measures of inflammation (albumin, C-reactive protein, white blood
cell count), and measures of dietary intake (urine phosphate, urine
urea nitrogen). Other endogenous filtration markers were also
considered as covariates (serum cystatin C, creatinine, and urea
nitrogen). Measurement methods and definitions for each of the
categorical variables have been described in the individual reports of
these studies.2,3,23–26,31
Statistical analyses
Summary statistics and scatter plots were used in initial exploratory
analyses to investigate the relationships between candidate variables
and the levels of serum cystatin C and serum creatinine in the
overall data set. Continuous variables were transformed so as to
create a linear relationship with log-transformed cystatin C and
creatinine in bivariate analyses. Sex and race were expressed as
binary factors indicating presence or absence of female sex and black
race, respectively. Diabetes and hypertension were expressed as
present or absent.
The relationships of cystatin C and creatinine with the predictor
variables were investigated by first performing separate linear
regressions to relate log-transformed cystatin C and creatinine to each
individual predictor variable after controlling for log-transformed GFR,
study, and the interaction between GFR and study. We repeated these
analyses using errors-in-variables regression analysis to incorporate
measurement in GFR into these models.32 A measurement error
variance of 0.015 was assumed for log-transformed GFR based on
analyses of the longitudinal variability in log-transformed baseline GFR
measurements spaced an average of approximately 3 months apart in
the MDRD Study and 0.6 months apart in the AASK Study.33
Sensitivity analyses were performed with different levels of measure-
ment error ranging from 0 to 0.020. Results were consistent for
measurement error variance ranging from 0.010 to 0.020, which covers
the plausible range. This errors-in-variables regression was repeated
after adding terms for age, female sex, and black race to the model for
each predictor variable.
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The relative strengths of relationships of the predictor variables
with log cystatin C and log creatinine were compared and
graphically displayed in scatter plots. For continuous variables,
regression coefficients were standardized to indicate the geometric
mean percent difference in either serum cystatin C or creatinine
associated with a 1.0 IQR higher value for the predictor variable; for
dichotomous predictor variables the regression coefficients are
expressed as the geometric mean percent difference in the response
variable associated with presence vs absence of the predictor. The
statistical significance of the difference between the coefficients for
the predictor variables with log cystatin C and log serum creatinine
was determined by applying the sign test to compare 800 bootstrap
samples with P-value of o0.001 indicating a significant difference
between the coefficients.
Analyses were computed using R (version 2; Free Software
Foundation Inc., Boston, MA, USA) and SAS software (version, 9.1;
SAS Institute Inc., Cary, NC, USA).
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